Net Income (Loss) Attributable to Parent in USD of Regen BioPharma Inc from Q4 2012 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Regen BioPharma Inc quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q4 2012 to Q3 2025.
  • Regen BioPharma Inc Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$2.000, a 100% increase year-over-year.
  • Regen BioPharma Inc Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$702K, a 5.98% decline year-over-year.
  • Regen BioPharma Inc annual Net Income (Loss) Attributable to Parent for 2025 was -$702K, a 5.06% decline from 2024.
  • Regen BioPharma Inc annual Net Income (Loss) Attributable to Parent for 2024 was -$668K, a 158% decline from 2023.
  • Regen BioPharma Inc annual Net Income (Loss) Attributable to Parent for 2023 was $1.16M, a 52.7% decline from 2022.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Regen BioPharma Inc Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$702K -$2 +$265K +100% 01 Jul 2025 30 Sep 2025 10-Q 11 Aug 2025
Q2 2025 -$967K -$167K -$37.2K -28.6% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025
Q1 2025 -$930K -$19.4K +$103K +84.2% 01 Jan 2025 31 Mar 2025 10-Q 28 May 2025
Q4 2024 -$1.03M -$515K -$370K -256% 01 Oct 2024 31 Dec 2024 10-Q 16 May 2025
Q3 2024 -$662K -$265K +$60.1K +18.5% 01 Jul 2024 30 Sep 2024 8-K 29 Nov 2024
Q2 2024 -$723K -$130K -$30.9K -31.1% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025
Q1 2024 -$692K -$122K -$67.5K -123% 01 Jan 2024 31 Mar 2024 10-Q 28 May 2025
Q4 2023 -$624K -$145K -$1.78M -109% 01 Oct 2023 31 Dec 2023 10-Q 16 May 2025
Q3 2023 $1.16M -$325K -$247K -317% 01 Jul 2023 30 Sep 2023 10-K 13 May 2025
Q2 2023 $1.4M -$99.2K -$67.1M -100% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024
Q1 2023 $68.5M -$55K +$67M +99.9% 01 Jan 2023 31 Mar 2023 10-Q 24 Apr 2024
Q4 2022 $1.43M $1.64M -$1.01M -38.2% 01 Oct 2022 31 Dec 2022 10-Q 19 Jan 2024
Q3 2022 $2.44M -$78K +$1.31M +94.4% 01 Jul 2022 30 Sep 2022 10-K 20 Nov 2023
Q2 2022 $1.14M $67M +$74.4M 01 Apr 2022 30 Jun 2022 10-Q 25 Jul 2023
Q1 2022 -$73.3M -$67.1M -$67.5M -15271% 01 Jan 2022 31 Mar 2022 10-Q 18 Apr 2023
Q4 2021 -$5.79M $2.64M +$979K +58.7% 01 Oct 2021 31 Dec 2021 10-Q 19 Jan 2023
Q3 2021 -$6.77M -$1.38M -$2.59M -215% 01 Jul 2021 30 Sep 2021 10-K 15 Nov 2022
Q2 2021 -$4.18M -$7.49M -$10.7M -334% 01 Apr 2021 30 Jun 2021 10-Q 22 Jul 2022
Q1 2021 $6.52M $442K +$4.52M 01 Jan 2021 31 Mar 2021 10-Q 21 Apr 2022
Q4 2020 $2M $1.67M -$1.42M -45.9% 01 Oct 2020 31 Dec 2020 10-Q 20 Jan 2022
Q3 2020 $3.41M $1.2M -$667K -35.7% 01 Jul 2020 30 Sep 2020 10-K 22 Dec 2021
Q2 2020 $4.08M $3.21M +$7.61M 01 Apr 2020 30 Jun 2020 10-Q/A 22 Dec 2021
Q1 2020 -$3.53M -$4.08M -$3.74M -1124% 01 Jan 2020 31 Mar 2020 10-Q 18 Aug 2021
Q4 2019 $215K $3.08M +$2.84M +1158% 01 Oct 2019 31 Dec 2019 10-Q 13 Aug 2021
Q3 2019 -$2.62M $1.87M +$2.56M 01 Jul 2019 30 Sep 2019 10-K 04 Aug 2021
Q2 2019 -$5.18M -$4.41M -$4.3M -3994% 01 Apr 2019 30 Jun 2019 10-Q 05 Aug 2021
Q1 2019 -$887K -$333K +$798K +70.5% 01 Jan 2019 31 Mar 2019 10-Q 05 Aug 2021
Q4 2018 -$1.68M $245K +$3.03M 01 Oct 2018 31 Dec 2018 10-Q 05 Aug 2021
Q3 2018 -$4.72M -$692K -$1.31M -211% 01 Jul 2018 30 Sep 2018 10-K 21 Jun 2021
Q2 2018 -$3.4M -$108K +$2.52M +95.9% 01 Apr 2018 30 Jun 2018 10-Q 24 Oct 2019
Q1 2018 -$5.92M -$1.13M +$181K +13.8% 01 Jan 2018 31 Mar 2018 10-Q 29 Aug 2019
Q4 2017 -$6.1M -$2.79M -$261K -10.3% 01 Oct 2017 31 Dec 2017 10-Q 12 Feb 2019
Q3 2017 -$5.84M $621K +$3.07M 01 Jul 2017 30 Sep 2017 10-K 27 Dec 2018
Q2 2017 -$8.91M -$2.62M -$266K -11.3% 01 Apr 2017 30 Jun 2017 10-Q 06 Aug 2018
Q1 2017 -$8.64M -$1.31M -$221K -20.3% 01 Jan 2017 31 Mar 2017 10-Q 14 May 2018
Q4 2016 -$8.42M -$2.52M -$667K -35.9% 01 Oct 2016 31 Dec 2016 10-Q 27 Jan 2017
Q3 2016 -$7.75M -$2.45M -$1.84M -307% 01 Jul 2016 30 Sep 2016 10-K 21 Dec 2016
Q2 2016 -$5.91M -$2.36M -$795K -50.9% 01 Apr 2016 30 Jun 2016 10-Q 01 Aug 2016
Q1 2016 -$5.11M -$1.09M +$7.72M +87.6% 01 Jan 2016 31 Mar 2016 10-Q 29 Apr 2016
Q4 2015 -$12.8M -$1.86M -$1.64M -747% 01 Oct 2015 31 Dec 2015 10-Q 27 Jan 2017
Q3 2015 -$11.2M -$601K -$406K -209% 01 Jul 2015 30 Sep 2015 10-K/A 28 Apr 2017
Q2 2015 -$10.8M -$1.56M -$1.4M -841% 01 Apr 2015 30 Jun 2015 10-K/A 28 Apr 2017
Q1 2015 -$9.39M -$8.81M -$8.63M -4633% 01 Jan 2015 31 Mar 2015 10-K/A 28 Apr 2017
Q4 2014 -$766K -$219K -$9.66K -4.61% 01 Oct 2014 31 Dec 2014 10-Q/A 28 Apr 2017
Q3 2014 -$756K -$195K -$76.7K -65.1% 01 Jul 2014 30 Sep 2014 10-K/A 28 Apr 2017
Q2 2014 -$680K -$166K -$91.2K -122% 01 Apr 2014 30 Jun 2014 10-K/A 28 Apr 2017
Q1 2014 -$588K -$186K -$116K -164% 01 Jan 2014 31 Mar 2014 10-K/A 28 Apr 2017
Q4 2013 -$473K -$210K -$118K -128% 01 Oct 2013 31 Dec 2013 10-K/A 28 Apr 2017
Q3 2013 -$355K -$118K 01 Jul 2013 30 Sep 2013 10-K 18 Dec 2014
Q2 2013 -$74.8K 01 Apr 2013 30 Jun 2013 10-K 18 Dec 2014
Q1 2013 -$70.5K 01 Jan 2013 31 Mar 2013 10-K 18 Dec 2014
Q4 2012 -$91.8K 01 Oct 2012 31 Dec 2012 10-K 18 Dec 2014

Regen BioPharma Inc Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2025 -$702K -$33.8K -5.06% 01 Oct 2024 30 Sep 2025 10-Q 11 Aug 2025
2024 -$668K -$1.82M -158% 01 Oct 2023 30 Sep 2024 10-K 13 May 2025
2023 $1.16M -$1.29M -52.7% 01 Oct 2022 30 Sep 2023 10-K 13 May 2025
2022 $2.44M +$9.21M 01 Oct 2021 30 Sep 2022 10-K 20 Nov 2023
2021 -$6.77M -$10.2M -298% 01 Oct 2020 30 Sep 2021 10-K 15 Nov 2022
2020 $3.41M +$6.04M 01 Oct 2019 30 Sep 2020 10-K 22 Dec 2021
2019 -$2.62M +$2.09M +44.4% 01 Oct 2018 30 Sep 2019 10-K 04 Aug 2021
2018 -$4.72M +$1.12M +19.2% 01 Oct 2017 30 Sep 2018 10-K 21 Jun 2021
2017 -$5.84M +$1.91M +24.7% 01 Oct 2016 30 Sep 2017 10-K 27 Dec 2018
2016 -$7.75M +$3.44M +30.8% 01 Oct 2015 30 Sep 2016 10-K 21 Dec 2016
2015 -$11.2M -$10.4M -1380% 01 Oct 2014 30 Sep 2015 10-K 21 Dec 2016
2014 -$756K -$401K -113% 01 Oct 2013 30 Sep 2014 10-K 18 Dec 2014
2013 -$355K 01 Oct 2012 30 Sep 2013 10-K 18 Dec 2014
* An asterisk sign (*) next to the value indicates that the value is likely invalid.